Upgrade to FINVIZ Elite to get real-time quotes, intraday charts, and advanced charting tools. Subscribe to Elite

REGN

Regeneron Pharmaceuticals, Inc

Jan 07 • 04:00PM ET

812.27

+35.73 4.60 %

Healthcare • Biotechnology • USA • NASD

Today, 7:50 AMBank of America double-upgrades Regeneron to Buy from Underperform and lifts price target to $860, citing stronger Eylea outlook and 2026 catalysts

Peers: AMGN BIIB GILD VRTX MRNA BMRN INCY EXEL IONS

| Held by: VTI VOO QQQ IVV SPY VTV IBB XLV JEPI QQQM

Scroll to Statements

Index	NDX, S&P 500	P/E	19.45	EPS (ttm)	41.77	Insider Own	3.76%	Shs Outstand	103.50M	Perf Week	4.95%
Market Cap	85.37B	Forward P/E	18.24	EPS next Y	44.54	Insider Trans	-0.19%	Shs Float	101.15M	Perf Month	13.07%
Enterprise Value	79.62B	PEG	3.60	EPS next Q	10.68	Inst Own	85.44%	Short Float	2.71%	Perf Quarter	39.27%
Income	4.58B	P/S	5.99	EPS this Y	-5.06%	Inst Trans	-0.99%	Short Ratio	2.74	Perf Half Y	47.00%
Sales	14.25B	P/B	2.76	EPS next Y	2.83%	ROA	11.80%	Short Interest	2.74M	Perf YTD	5.23%
Book/sh	294.00	P/C	10.10	EPS next 5Y	5.06%	ROE	15.19%	52W High	792.77 2.46%	Perf Year	13.11%
Cash/sh	80.40	P/FCF	20.22	EPS past 3/5Y	-18.94% 15.74%	ROIC	13.60%	52W Low	476.49 70.47%	Perf 3Y	12.58%
Dividend Est.	2.97 (0.37%)	EV/EBITDA	18.28	Sales past 3/5Y	-4.04% 16.71%	Gross Margin	81.71%	Volatility	1.85% 2.26%	Perf 5Y	69.82%
Dividend TTM	3.52 (0.43%)	EV/Sales	5.59	EPS Y/Y TTM	0.50%	Oper. Margin	26.88%	ATR (14)	18.96	Perf 10Y	47.63%
Dividend Ex-Date	Nov 20, 2025	Quick Ratio	3.33	Sales Y/Y TTM	2.89%	Profit Margin	32.13%	RSI (14)	69.50	Recom	1.73
Dividend Gr. 3/5Y	- -	Current Ratio	4.06	EPS Q/Q	18.05%	SMA20	6.46%	Beta	0.40	Target Price	821.00
Payout	0.00%	Debt/Eq	0.09	Sales Q/Q	0.90%	SMA50	12.27%	Rel Volume	1.26	Prev Close	776.54
Employees	15106	LT Debt/Eq	0.09	Earnings	Oct 28 BMO	SMA200	34.01%	Avg Volume	999.38K	Price	812.27
IPO	Apr 02, 1991	Option/Short	Yes / Yes	EPS/Sales Surpr.	22.53% 4.51%	Trades		Volume	1,263,930	Change	4.60%

Date	Action	Analyst	Rating Change	Price Target Change
Today	Upgrade	BofA Securities	Underperform → Buy	$860
Dec-03-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$767
Nov-24-25	Resumed	Truist	Buy	$798
Nov-24-25	Initiated	HSBC Securities	Buy	$255
Nov-13-25	Initiated	Scotiabank	Sector Perform	$650
Aug-14-25	Initiated	Rothschild & Co Redburn	Buy	$890
Jun-30-25	Downgrade	Argus	Buy → Hold
May-30-25	Downgrade	Wells Fargo	Overweight → Equal Weight	$580
May-30-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$662
May-14-25	Upgrade	Citigroup	Neutral → Buy	$700
Apr-22-25	Resumed	Cantor Fitzgerald	Overweight	$695
Feb-05-25	Upgrade	Leerink Partners	Market Perform → Outperform	$762 → $834
Jan-16-25	Downgrade	UBS	Buy → Neutral	$1130 → $738
Dec-10-24	Resumed	BofA Securities	Underperform	$565
Nov-15-24	Initiated	Wolfe Research	Outperform	$1150
Nov-14-24	Initiated	Citigroup	Neutral	$895
Sep-24-24	Downgrade	Leerink Partners	Outperform → Market Perform	$1175 → $1077
Mar-12-24	Initiated	Bernstein	Outperform	$1125
Jan-12-24	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$884 → $1076
Nov-09-23	Initiated	Deutsche Bank	Hold	$800

Show Previous Ratings

Today 04:05PM	Regeneron Stock Lagged Behind the S&P 500 Last Year. Why This Firm Moved Off the Sidelines. (Barrons.com)
12:10PM	Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report? (Zacks)
11:40AM	REGN vs. ILMN: Which Stock Is the Better Value Option? (Zacks)
11:20AM	Why Regeneron (REGN) Stock Is Trading Up Today (StockStory)
09:41AM	Wayfair upgraded, Instacart initiated: Wall Street's top analyst calls (The Fly)
07:37AM	Loading…
07:37AM	BofA double-upgrades Regeneron, citing stronger Eylea outlook and 2026 catalysts (Investing.com)
Jan-06-26 11:40AM	REGN vs. ILMN: Which Stock Should Value Investors Buy Now? (Zacks)
08:55AM	Why Investors Need to Take Advantage of These 2 Medical Stocks Now (Zacks)
07:18AM	Regeneron Pharmaceuticals' Quarterly Earnings Preview: What You Need to Know (Barchart)
05:30AM	Big Pharma Has More Going for It Than Obesity Drugs (The Wall Street Journal)
04:40AM	The Zacks Analyst Blog Eli Lilly, Medtronic, Intuitive Surgical, Regeneron Pharmaceuticals and Johnson & Johnson (Zacks)
Jan-05-26 01:45PM	KYMR Skyrockets 82.4% in a Year: More Upside Potential in 2026? (Zacks)
10:58AM	Intellia Stock Declines Around 55% in 3 Months: Here's Why (Zacks)
07:41AM	Watch 5 AI-Powered Medical Stocks for a Strong Portfolio in 2026 (Zacks)
Jan-02-26 04:05PM	Regeneron to Report Fourth Quarter and Full Year 2025 Financial and Operating Results and Host Conference Call and Webcast on January 30, 2026 (GlobeNewswire)
09:53AM	Loading…
09:53AM	Will ANIP's Rare Disease Franchise Maintain Momentum in 2026? (Zacks)
08:40AM	REGN Soars 41% in Six Months: Is There More Upside Potential in 2026? (Zacks)
Dec-31-25 08:10AM	BAYRY's 2025 Revival: Will the Momentum Continue in 2026? (Zacks)
01:30AM	It's Earnings Warning Season. How to Profit From Others' Misery. (Barrons.com)
Dec-30-25 11:04PM	3 Reasons to Avoid REGN and 1 Stock to Buy Instead (StockStory)
04:31PM	Stocks Fall Slightly in Thin Holiday Trade (Barchart)
11:06AM	Stocks Slip as Bond Yields Rise (Barchart)
Dec-28-25 11:39PM	3 Cash-Heavy Stocks We Approach with Caution (StockStory)
Dec-26-25 11:24PM	Morgan Stanley Sees Policy Risks Receding for Regeneron (REGN) (Insider Monkey)
Dec-23-25 01:00AM	Dupixent (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial Asthma (GlobeNewswire)
Dec-22-25 04:05PM	Regeneron Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
07:11AM	Illumina (ILMN) Surges 3.3%: Is This an Indication of Further Gains? (Zacks)
Dec-19-25 05:40PM	Dow Jones' Merck, Other Drugmakers Strike Drug-Pricing Bargains With Trump (Investor's Business Daily)
04:30PM	Nine Drugmakers Strike Deals With Trump, With More to Come (Bloomberg)
07:44AM	Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030 (PR Newswire)
07:03AM	Loading…
Dec-16-25 07:03AM	Pfizer Adds to Its Big Bet on Weight Loss Drugs (MarketBeat)
Dec-14-25 03:30AM	Kymera Had a Big Week. This Secretive Hedge Fund Bought $172 Million of Its Stock. (Barrons.com)
Dec-13-25 10:21AM	2 Reasons to Buy Regeneron Stock Like There's No Tomorrow (Motley Fool)
Dec-12-25 09:35AM	Regeneron (REGN) Just Flashed Golden Cross Signal: Do You Buy? (Zacks)
Dec-09-25 11:50AM	Pfizer Turns to China for Trial Weight Loss Drug. Congress Is Worried About Chinese Biotechs. (Barrons.com)
Dec-08-25 04:07PM	Kymera Rockets, Pulling Nurix Higher. Does It Have The Next Dupixent? (Investor's Business Daily)
12:07PM	Regeneron's (REGN) Recovery and Dupixent Strength Support BMO's Outperform Rating (Insider Monkey)
Dec-07-25 04:30PM	Lynozyfic (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment (GlobeNewswire)
Dec-05-25 11:30AM	Jazz (JAZZ) Up 24.5% Since Last Earnings Report: Can It Continue? (Zacks)
Dec-04-25 09:26PM	Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory (Insider Monkey)
11:30AM	Why Is Beam Therapeutics (BEAM) Up 15.9% Since Last Earnings Report? (Zacks)
Dec-03-25 09:35AM	Oracle initiated, Uber upgraded: Wall Street's top analyst calls (The Fly)
09:15AM	Here Are Wednesdays Top Wall Street Analyst Upgrades and Downgrades: American Eagle Outfitters, Equinix, Garmin, Honeywell, Uber, Wendys and More (24/7 Wall St.)
Dec-02-25 02:21PM	REGN & Tessera Collaborate to Develop Gene-Editing Therapy for AATD (Zacks)
09:48AM	Stock Market Today: Nasdaq Rises As AI Stocks Nvidia, Palantir, Astera Rally (Live Coverage) (Investor's Business Daily)
Dec-01-25 12:49PM	Regeneron and Tessera join forces to forge in vivo AATD gene therapy (Pharmaceutical Technology)
10:51AM	5 Healthcare Names to Watch as Sector Rotation Is in Full Swing (MarketBeat)
09:48AM	REGN Gains 21.5% in a Month: Time to Buy, Sell or Hold the Stock? (Zacks)
07:00AM	Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD) (GlobeNewswire)
06:54AM	Regeneron inks gene editing deal with startup Tessera (BioPharma Dive)
Nov-30-25 11:15PM	Should You Buy This Biotech Stock That Just Gained 5% in 1 Day? (Motley Fool)
Nov-28-25 09:59AM	Can NTLA's In Vivo Pipeline Drive Long-Term Growth Amid Rivalry? (Zacks)
07:11AM	Is Regeneron Pharmaceuticals Stock Underperforming the S&P 500? (Barchart)
Nov-27-25 11:30AM	Regeneron (REGN) Up 20.2% Since Last Earnings Report: Can It Continue? (Zacks)
08:15AM	BEAM vs. NTLA: Which Gene Editing Stock Holds More Potential? (Zacks)
Nov-26-25 01:37PM	Dupixent gains chronic spontaneous urticaria indication in Europe (Pharmaceutical Technology)
05:30AM	Hedge Funds Pile Into Health Stocks Leading Market in Rotation (Bloomberg)
Nov-25-25 10:45AM	SNY & REGN's Dupixent Gets EU Nod for Chronic Spontaneous Urticaria (Zacks)
01:00AM	Dupixent (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU) (GlobeNewswire)
Nov-24-25 04:11PM	Bristol Myers Pops On A 'Surprisingly Positive' Update From Key Rival Bayer (Investor's Business Daily)
07:58AM	1 Reason Why Shares of Regeneron Pharmaceuticals Are Surging This Month (Motley Fool)
Nov-23-25 02:51PM	Jim Cramer Says He "Should Have Been Recommending Regeneron" (Insider Monkey)
Nov-22-25 08:30AM	This Medicare premium just crossed $200 a month for the first time. Heres why. (MarketWatch)
Nov-21-25 10:19AM	NTLA Declines 67% in a Month: Should You Buy, Sell or Hold the Stock? (Zacks)
10:15AM	This Month's Stock Trend Hasn't Been AI. Here's What's Been Climbing Instead (Investopedia)
09:06AM	Here's How ANIP's Rare Disease Portfolio Is Driving Top-line Growth (Zacks)
08:52AM	Are Wall Street Analysts Bullish on Regeneron Pharmaceuticals Stock? (Barchart)
Nov-20-25 05:05PM	Stocks to Watch Thursday Recap: Walmart, Nvidia, Cracker Barrel, Regeneron (The Wall Street Journal)
01:36PM	Stocks to Watch Thursday: Walmart, Nvidia, Cracker Barrel, Regeneron (The Wall Street Journal)
11:08AM	Stock Market Today: Nasdaq, S&P 500 Stage Modest Comeback After Post-Earnings Nvidia Decline (TheStreet)
09:19AM	REGN Gets EC Nod for Libtayo Label Expansion, FDA Clears Monthly Eylea HD (Zacks)
07:25AM	Regenerons Eylea franchise boosted by pair of FDA approvals (Pharmaceutical Technology)
06:36AM	With new approvals, Regenerons higher-dose Eylea gets more competitive (BioPharma Dive)
Nov-19-25 04:10PM	EYLEA HD (aflibercept) Injection 8 mg Approved by FDA for the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing Across Approved Indications (GlobeNewswire)
07:00AM	Libtayo (cemiplimab) Approved in the European Union as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with High Risk of Recurrence after Surgery and Radiation (GlobeNewswire)
Nov-18-25 04:45AM	Is Regeneron Pharmaceuticals (REGN) One of the Best Gene-Editing Stocks to Buy According to Hedge Funds? (Insider Monkey)
Nov-17-25 04:22PM	Stock Market Today: Dow Skids, AI Play Dives As Peter Thiel Exits; Netflix Divvies Up Its Shares (Live Coverage) (Investor's Business Daily)
03:02PM	Stock Market Today: Dow Dips As Biotech Eyes Entry; Why Netflix Went From $1,100 To $111 (Live Coverage) (Investor's Business Daily)
Nov-14-25 04:02PM	Bristol Myers Slouches 4% After Experts Say Its Heart Drug Will Fail (Investor's Business Daily)
08:58AM	Can NTLA Stock Bounce Back in 2026 After Recent Pipeline Setbacks? (Zacks)
Nov-13-25 09:45AM	Nike upgraded, Dollar Tree downgraded: Wall Street's top analyst calls (The Fly)
07:00AM	Regeneron Highlights Progress at American Society of Hematology (ASH), with Updated Data in Multiple Myeloma, Lymphoma and Paroxysmal Nocturnal Hemoglobinuria Programs (GlobeNewswire)
05:15AM	Here Are the Top Growth Healthcare Stocks Every New Investor Should Know (Motley Fool)
Nov-12-25 07:49PM	Analyst Report: Regeneron Pharmaceuticals, Inc. (Morningstar Research)
12:26PM	Bayer Q3 Earnings Beat Estimates on Crop Science Business Gains (Zacks)
Nov-10-25 04:20PM	Merck's Heart Pill Slashes Cholesterol Levels in Test Patients (Barrons.com)
06:56AM	Dupixent set for ninth US approval after Phase III AFRS success (Clinical Trials Arena)
04:25AM	Winners And Losers Of Q3: Regeneron (NASDAQ:REGN) Vs The Rest Of The Immuno-Oncology Stocks (StockStory)
Nov-08-25 02:32PM	Merck Takes On Amgen, Regeneron, Lowering Stubbornly High Cholesterol By 60% (Investor's Business Daily)
10:46AM	Phase 2 Trials Demonstrating Antithrombotic Effect of Two Novel Regeneron Factor XI Antibodies Presented at American Heart Association Scientific Sessions and Published in The Lancet (GlobeNewswire)
Nov-07-25 05:09PM	Analyst Report: Intellia Therapeutics, Inc. (Morningstar Research)
09:56AM	Intellia Q3 Loss Narrower Than Expected, Stock Down on Pipeline Trouble (Zacks)
08:00AM	Dupixent (dupilumab) Pivotal Trial Met All Primary and Secondary Endpoints, Reducing Signs and Symptoms of Allergic Fungal Rhinosinusitis (AFRS); sBLA Accepted for FDA Priority Review (GlobeNewswire)
Nov-05-25 10:48AM	Ultragenyx Q3 Earnings and Sales Miss Estimates, Increase Y/Y (Zacks)
Nov-04-25 11:31PM	Michael Burry Is Super-Bearish On Palantir With 5 Million Puts (Benzinga)
12:38AM	5 Revealing Analyst Questions From Regeneron's Q3 Earnings Call (StockStory)
Nov-03-25 04:05PM	Regeneron Announces Investor Conference Presentations (GlobeNewswire)
07:58AM	2 Beaten-Down Stocks That Could Be About to Rally (Motley Fool)
Oct-31-25 09:33AM	Sometimes the only winning move is not to play, says Michael Burry in bubble warning (MarketWatch)
08:37AM	AstraZenecas gMG drug fails to fend off rivals despite Phase III win (Clinical Trials Arena)

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Bassler Bonnie L	Director	Jan 07 '26	Proposed Sale	800.00	1,500	1,200,000		Jan 07 12:03 PM
YANCOPOULOS GEORGE	Bd. Co-Chair, President & CSO	Dec 31 '25	Option Exercise	0.00	28,570	0	339,030	Jan 05 05:54 PM
SCHLEIFER LEONARD S	Bd. Co-Chair, President & CEO	Dec 31 '25	Option Exercise	0.00	28,570	0	243,093	Jan 05 05:53 PM
SING GEORGE L	Director	Dec 30 '25	Option Exercise	520.01	9,212	4,790,332	37,040	Dec 31 05:05 PM
YANCOPOULOS GEORGE	Bd. Co-Chair, President & CSO	Dec 09 '25	Option Exercise	555.67	146,815	81,580,691	442,334	Dec 11 04:27 PM
SCHLEIFER LEONARD S	Bd. Co-Chair, President & CEO	Dec 09 '25	Option Exercise	555.67	172,723	95,976,989	369,668	Dec 11 04:23 PM
LAROSA JOSEPH J	EVP General Counsel and Secret	Nov 20 '25	Option Exercise	555.67	14,450	8,029,431	35,525	Nov 24 04:07 PM
Bassler Bonnie L	Director	Nov 20 '25	Option Exercise	371.40	760	282,264	2,308	Nov 24 04:05 PM
Bassler Bonnie L	Director	Nov 20 '25	Sale	750.00	760	570,000	1,548	Nov 24 04:05 PM
Bassler Bonnie L	Director	Nov 20 '25	Proposed Sale	750.00	760	570,000		Nov 20 02:31 PM
Pitofsky Jason	VP Controller	Nov 07 '25	Sale	651.43	431	280,766	4,233	Nov 10 04:37 PM
Jason Pitofsky	Officer	Nov 07 '25	Proposed Sale	651.00	431	280,581		Nov 07 05:06 PM
POON CHRISTINE A	Director	Oct 29 '25	Option Exercise	520.01	6,500	3,380,065	8,852	Oct 31 04:09 PM
POON CHRISTINE A	Director	Oct 30 '25	Option Exercise	520.01	2,712	1,410,267	5,064	Oct 31 04:09 PM
POON CHRISTINE A	Director	Oct 29 '25	Sale	654.27	6,500	4,252,745	2,352	Oct 31 04:09 PM
MURPHY ANDREW J	EVP Research	Oct 29 '25	Option Exercise	555.67	35,000	19,448,450	84,074	Oct 31 04:06 PM
Christine Poon	Director	Oct 29 '25	Proposed Sale	652.91	6,500	4,243,915		Oct 29 04:36 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

REGN

Regeneron Pharmaceuticals, Inc

Upgrade your FINVIZ experience